THERAPEUTICSMD INC (TXMD)

US88338N2062 - Common Stock

1.11  -0.03 (-2.63%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to TXMD. TXMD was compared to 192 industry peers in the Pharmaceuticals industry. While TXMD seems to be doing ok healthwise, there are quite some concerns on its profitability. TXMD has a correct valuation and a medium growth rate.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year TXMD has reported negative net income.
TXMD had a negative operating cash flow in the past year.
TXMD had negative earnings in 4 of the past 5 years.
TXMD had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of TXMD (-8.38%) is better than 72.83% of its industry peers.
TXMD has a Return On Equity of -12.24%. This is in the better half of the industry: TXMD outperforms 76.09% of its industry peers.
Industry RankSector Rank
ROA -8.38%
ROE -12.24%
ROIC N/A
ROA(3y)-0.57%
ROA(5y)-33.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

TXMD's Gross Margin of 81.58% is amongst the best of the industry. TXMD outperforms 86.41% of its industry peers.
In the last couple of years the Gross Margin of TXMD has grown nicely.
TXMD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.88%
GM growth 5Y3.8%

More info and screens

6

2. Health

2.1 Basic Checks

TXMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TXMD has more shares outstanding
TXMD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for TXMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

TXMD has an Altman-Z score of -33.24. This is a bad value and indicates that TXMD is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TXMD (-33.24) is worse than 90.76% of its industry peers.
TXMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -33.24
ROIC/WACCN/A
WACC10.67%

2.3 Liquidity

A Current Ratio of 2.03 indicates that TXMD has no problem at all paying its short term obligations.
TXMD has a Current ratio (2.03) which is comparable to the rest of the industry.
A Quick Ratio of 2.03 indicates that TXMD has no problem at all paying its short term obligations.
TXMD has a Quick ratio (2.03) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.03
Quick Ratio 2.03

More info and screens

4

3. Growth

3.1 Past

TXMD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -103.85%.
The Revenue for TXMD has decreased by -18.57% in the past year. This is quite bad
The Revenue for TXMD have been decreasing by -39.53% on average. This is quite bad
EPS 1Y (TTM)-103.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.14%
Revenue 1Y (TTM)-18.57%
Revenue growth 3Y-72.82%
Revenue growth 5Y-39.53%
Sales Q2Q%1194%

3.2 Future

The Earnings Per Share is expected to grow by 20.36% on average over the next years. This is a very strong growth
TXMD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.13% yearly.
EPS Next Y192.11%
EPS Next 2Y70.91%
EPS Next 3Y34.76%
EPS Next 5Y20.36%
Revenue Next Year350%
Revenue Next 2Y113.31%
Revenue Next 3Y66.91%
Revenue Next 5Y37.14%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

TXMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 3.11 indicates a rather cheap valuation of TXMD.
98.91% of the companies in the same industry are more expensive than TXMD, based on the Price/Forward Earnings ratio.
TXMD is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.54, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 3.11

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

TXMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TXMD's earnings are expected to grow with 34.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y70.91%
EPS Next 3Y34.76%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TXMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERAPEUTICSMD INC

NASDAQ:TXMD (1/8/2025, 3:18:05 PM)

1.11

-0.03 (-2.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-11 2024-11-11/amc
Earnings (Next)N/A N/A
Inst Owners29.64%
Inst Owner Change0%
Ins Owners1.77%
Ins Owner Change0.03%
Market Cap12.80M
Analysts43.33
Price Target5.1 (359.46%)
Short Float %0.19%
Short Ratio0.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.11
P/S 8.02
P/FCF N/A
P/OCF N/A
P/B 0.47
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)0.36
Fwd EY32.16%
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0.14
BVpS2.35
TBVpS1.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.38%
ROE -12.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 81.58%
FCFM N/A
ROA(3y)-0.57%
ROA(5y)-33.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.88%
GM growth 5Y3.8%
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.03
Quick Ratio 2.03
Altman-Z -33.24
F-Score3
WACC10.67%
ROIC/WACCN/A
Cap/Depr(3y)110.08%
Cap/Depr(5y)867.47%
Cap/Sales(3y)28.97%
Cap/Sales(5y)27.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-103.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.14%
EPS Next Y192.11%
EPS Next 2Y70.91%
EPS Next 3Y34.76%
EPS Next 5Y20.36%
Revenue 1Y (TTM)-18.57%
Revenue growth 3Y-72.82%
Revenue growth 5Y-39.53%
Sales Q2Q%1194%
Revenue Next Year350%
Revenue Next 2Y113.31%
Revenue Next 3Y66.91%
Revenue Next 5Y37.14%
EBIT growth 1Y-106.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-112.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-112.46%
OCF growth 3YN/A
OCF growth 5YN/A